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Abstract
Adoptive therapy of malignant diseases with tumor-specific cytotoxic T cells showed remarkable efficacy in recent trials.
Repetitive T cell receptor (TCR) engagement of target antigen, however, inevitably ends up in hypo-responsive cells with
terminally differentiated KLRG-1
+ CD57
+ CD7
2 phenotype limiting their therapeutic efficacy. We here revealed that hypo-
responsiveness of CMV-specific late-stage CD8
+ T cells is due to reduced TCR synapse formation compared to younger cells.
Membrane anchoring of TCR components contributes to T cell hypo-responsiveness since dislocation of galectin-3 from the
synapse by swainsonine restored both TCR synapse formation and T cell response. Transgenic expression of a CD3-zeta
signaling chimeric antigen receptor (CAR) recovered hypo-responsive T cells to full effector functions indicating that the
defect is restricted to TCR membrane components while synapse formation of the transgenic CAR was not blocked. CAR
engineered late-stage T cells released cytokines and mediated redirected cytotoxicity as efficiently as younger effector T
cells. Our data provide a rationale for TCR independent, CAR mediated activation in the adoptive cell therapy to avoid hypo-
responsiveness of late-stage T cells upon repetitive antigen encounter.
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Introduction
Adoptive T cell therapy recently showed significant success in
the treatment of malignant diseases [1,2]. Upon adoptive transfer
tumor-specific T cells migrate to the tumor tissue, engage antigen
and mediate a pro-inflammatory anti-tumor response. At the
molecular level, the TCR components form an immunological
synapse at the interface of the effector T cell to the peptide-MHC
complexes of the antigen-presenting cell to initiate T cell activation
by downstream signaling [3]. Lipid rafts in the membrane
substantially impact this process and the distribution and the
amount of lipid rafts substantially changes during T cell
differentiation. In particular there are clear differences in the lipid
raft distribution and TCR synapse formation between naı ¨ve and
effector memory cells; naı ¨ve T cells have fewer rafts in their
plasma membrane and require CD28 costimulation to amplify
TCR signaling whereas effector memory T cells have more rafts
and the signal amplifies in the absence of costimulation [3,4]. At
the moment several companies are developing drugs targeting
molecules at the immunological synapse. Some biochemical
substances or monoclonal antibodies are currently tested in
clinical studies to improve the efficacy of immunological synapse
formation for cancer immunotherapy [5]. Success in these studies
was already reported, since ipilimumab, a monoclonal antibody
against CTLA-4, produces durable, complete responses in a small
but consistent proportion of melanoma patients [5].
With respect to the therapeutic efficacy central memory T(CM)
showed superior over effector memory T(EM) cells by proliferating
more rapidly upon antigen encounter and by persisting longer
upon adoptive transfer, thereby promoting repetitive migration
into the draining lymph node and re-entering circulation [2,6].
Repetitive antigen engagement, however, drives T cells to progress
in the differentiation pathway inevitably ending up in terminally
differentiated cells with the KLRG-1
+ CD45RO
bright CD57
+
CD7
2 late-stage phenotype [7,8]. T cells in this stage show a high
activation threshold, a high propensity to undergo activation
induced cell death (AICD) [9] and a hypo-responsiveness upon
TCR stimuli [10]. A hypo-responsive TCR, however, limits the
therapeutic efficacy of adoptive T cell therapy [11].
To engraft adoptive T cell therapy with defined specificity,
patient’s T cells are ex vivo engineered with a transgenic TCR or
alternatively with a chimeric antigen receptor (CAR) that in
contrast to the TCR consists of a single polypeptide chain with an
extracellular antibody-derived binding domain and the intracel-
lular CD3-zeta signaling moiety [12]. While a transgenic TCR
with CD3-zeta signaling domain forms synapses and initiates
downstream signaling and effector functions independently of the
endogenous TCR/CD3 complex [13], the functional activity of a
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components of the endogenous TCR complex in the Jurkat T cell
model [14]. No data, however, are so far available for engineered
peripheral blood T cells, in particular for those T cells that
experienced repetitive antigen engagement. The issue is consid-
ered critical for the success of clinical T cell therapy in order to
control tumor growth by adoptively transferred T cells in long-
term.
We here elucidated that the hypo-responsiveness of the
physiological TCR in terminally differentiated, late-stage T cells
is due to membrane anchoring of TCR components whereas the
down-stream signaling pathway is still functional. Consequently,
late-stage T cells are susceptible to CAR CD3-zeta-mediated
activation resulting in cytokine release and redirected cytotoxicity
despite hypo-responsive TCR. Our data provide a rationale for
CAR redirected T cell activation in the adoptive immunotherapy
to avoid hypo-responsiveness upon repetitive antigen encounter.
Results
Late-stage T cells are hypo-responsive to TCR stimulation
To record TCR mediated activation of terminally differentiated
T cell subsets we isolated CMV-specific CD8
+ T cells from CMV
infected, HIV
2, HLA-A2
+ individuals. CMV-specific T cells,
identified by pp65 tetramer binding, predominantly consist of late-
stage KLRG-1
+ CD57
+ CD7
2 T cells and a minor subset of
intermediate-stage KLRG-1
2/low CD57
2 CD7
+ cells (Fig. S1).
Cells of both subsets expressed TCR-alpha/beta and CD3-epsilon
at similar levels and equally bound pp65 CMV tetramers
indicating similar amounts of CMV-specific TCR molecules on
their cell surface (Fig. S1).
CMV pp65-driven T cell activation, indicated by increase in
IFN-gamma expression, was substantially reduced in T cells of the
CD7
2 late-stage subset compared to CD7
+ intermediate-stage T
cells (Fig. 1A). Activation was CMV-specific since HIV peptide as
control did not induce IFN-gamma in those T cells. Antigen-
independent TCR cross-linking moreover resulted in less activa-
tion of late-stage T cells compared to T cells in intermediate-stage
of terminal differentiation. CD107a staining was reduced in late-
stage T cells compared to intermediate-stage T cells upon pp65
CMV mediated activation indicating diminished cytolytic degran-
ulation (Fig. 1B). As controls no increase in degranulation was
monitored in CMV-specific T cell subsets when activated without
CD49d/CD28 costimulation or in absence of antigen. Repression
of T cell response is not restricted to CMV-specific T cells since
polyclonal T cells in late-stage differentiation showed the same
hypo-responsiveness after CD3 stimulation in presence of CD28
costimulation or IL-2 (Figs. S2A & B). Taken together we conclude
that late-stage T cells are hypo-responsive in TCR mediated
activation compared to intermediate-stage T cells.
Late-stage T cells are deficient in TCR synapse formation
We asked whether hypo-responsiveness of late-stage T cells is
due to impaired TCR synapse formation. T cells were stimulated
with the immobilized agonistic anti-CD3 antibody, alternatively
with anti-CD2 antibodies, in presence of CD28 costimulation and
TCR synapse formation was recorded by confocal microscopy.
Within 5 min upon stimulation intermediate-stage T cells showed
coalescence of TCR components into lipid rafts and TCR synapse
formation in the contact region to antigen (Fig. 2). Late-stage T
cells, in contrast, formed synapses with substantial delay, i.e., after
10 min, and with lower densities. No synapse formation was
observed in T cells incubated on poly-L-lysine coated surfaces as
control (data not shown). Both T cell subsets, however, recruited
CD2 into lipid rafts within the same time upon CD2/CD28
stimulation indicating that impaired TCR synapse formation in
late-stage T cells is restricted to TCR components and not due to
an overall decrease in membrane fluidity.
We asked whether impaired TCR synapse formation is due to
reduced membrane mobility of TCR components as a conse-
quence of galectin-3 binding to branched sugar residues as
reported for other T cell subsets [15]. As shown in Fig. 3A,
galectin-3 was located in the cytoplasm of resting late-stage T cells
and translocated to the cell membrane upon CD3/CD28
stimulation where it co-localized with CD3-epsilon and TCR-
alpha/beta. In contrast, intermediate-stage T cells showed no co-
localization of galectin-3 with CD3-epsilon or TCR-alpha/beta.
Galectin-3 was moreover expressed at higher levels and further-
more increased after CD3/CD28 activation in late-stage T cells
compared to intermediate-stage T cells.
To revert galectin-3 block of TCR components, cells were
treated with swainsonine that inhibits alpha-mannosidase II
leading to impaired N-glycosylation and loss of branched sugar
structures required for galectin-3 binding [15]. After treatment of
late-stage T cells with swainsonine, galectin-3 no longer translo-
cated to the cell membrane. TCR synapse formation upon antigen
engagement occurred with similar efficiency and time frame in
swansonine treated late-stage T cells as in intermediate-stage T
cells (Fig. 3B). Treated late-stage T cells accordingly showed
improved activation with respect to the secreted IFN-gamma
levels, the number of IFN-gamma
+ cells and the cytolytic
degranulation of cells indicated by CD107a staining (Fig. 3C).
Data indicate that impaired TCR synapse formation of late-stage
T cells can be restored by preventing galectin-3 mediated
membrane anchoring of TCR components.
Transgenic expression of a CD3-zeta signaling CAR
overcomes hypo-responsiveness of late-stage T cells
Based on the assumption that hypo-responsiveness of late-stage
T cells is exclusively due to impaired synapse formation without
additional impairments, we hypothesized two fundamental
consequences: (i) the TCR down-stream signaling pathway is
functional and (ii) a CD3-zeta signaling CAR bypasses the TCR
hypo-responsiveness redirecting late-stage T cells to a full anti-
tumor cell response. We therefore engineered those T cells with a
CAR with MHC-independent binding specificity for carcinoem-
bryonic antigen (CEA) and the CD3-zeta signaling endodomain
for T cell activation. Upon retroviral transduction T cells of the
CD7
2 late-stage and CD7
+ intermediate-stage subset expressed
the CAR with nearly same efficiencies (Fig. 4A). Life imaging
revealed that late-stage T cells as efficiently formed CAR synapses
as did intermediate-stage T cells upon CAR engagement of
antigen. CAR synapse formation occurred with similar time
kinetics in both T cell subsets (Fig. 4B). Galectin-3 remained in the
cytoplasm upon antigen engagement without translocation to the
cell surface (Fig. 4C) No co-localization of galectin-3 with the TCR
occurred in those cells. Accordingly, CAR engagement of CEA
+
target cells activated late-stage T cells equally efficiently as
intermediate-stage T cells indicated by increase in IFN-gamma
secretion and induction of redirected cytolysis (Fig. 4D). CAR-
mediated T cell activation was antigen-triggered since co-
incubation with CEA
2 tumor cells did not induce IFN-gamma
secretion or cytolysis. Incubation of non-modified T cells with
tumor cells did not induce T cell activation. We conclude that
TCR hypo-responsiveness of late-stage T cells can be circumvent-
ed by a transgenic CAR that triggers the TCR/CD3-zeta down-
stream signaling pathway.
CAR Overcomes TCR Unresponsiveness
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Repetitive antigen engagement of adoptively transferred T cells
will inevitably end in terminally differentiated late-stage T cells
[2,16] which are functionally exhausted und dampen the
therapeutic efficacy [10,17,18]. This phenomenon is of particular
relevance when redirecting T cells with defined specificity towards
target cells. While reduced response of early-stage CD45RO
+ T
cells is due to down-regulated expression of TCR components,
especially the CD3-gamma chain, following ligand triggering [19],
we here revealed that T cells in more differentiated stages, in
particular in the KLRG-1
2/low CD57
2 CD7
+ intermediate and
KLRG-1
+ CD57
+ CD7
2 late-stage of terminal differentiation,
express the TCR and bind specific tetramers with similar
efficiencies; CD7
2 T cells, however, respond less efficiently with
IFN-gamma and cytolytic degranulation than the CD7
+ KLRG-
1
2/low CD57
2 T cells. While hypo-responsiveness of intermediate-
stage T cells is due to blockade through PD-1/PD-1L interaction,
Figure 1. CMV-specific, late-stage T cells are hypo-responsive upon TCR stimulation compared to intermediate-stage T cells. (A)
Freshly isolated PBMC’s from CMV patients were activated by incubation with CMV pp65 peptide or for control with the HIV peptide or Cytostim,
respectively, for 6 hrs. CMV-specific cells were identified by staining them with the PE-conjugated MHC tetrameric complexes and mAbs specific to
CD8, CD7, CD45RO and subsequently recorded for IFN-gamma production by staining the with anti-human IFN-gammamAb. The number of
tetramer-positive cells of the CD7
2 and CD7
+ cells of the CD8
+ CD45RO
+ subset with and without IFN-gammaproduction was recorded by flow
cytometry. Histograms of one representative donor from five CMV patients is shown. Overlays of control peptide stimulated (thin line), Cytostim-
activated (dotted line), and CMV peptide-stimulated (bold line) cells are shown. (B) CD107a was monitored by flow cytometry of CMV-specific CD8
+
CD45RO
+ T cells of the CD7
2 and CD7
+ subsets after or without CD49d/CD28 stimulation in presence or absence of CMV peptide. Histograms of one
representative donor from five CMV patients is shown (CD107a: bold line; isotype control: thin line). Data in Fig. 1 A & B represent mean values 6
standard error of the mean (SEM) of five donors and were compared using a paired t-test. * p,0.05.
doi:10.1371/journal.pone.0030713.g001
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T cells show impaired TCR synapse formation, which is due to a
selective immobility of the TCR components in the cell membrane
and likely mediated by galectin-3. Our conclusion is sustained by
the observation that swainsonine, which prevents galectin-3
mediated anchoring of membrane proteins by preventing
branched sugar formation [15], restored the TCR synapse
formation and T cell response. Hypo-responsiveness of late-stage
T cells thereby seems to be due to the same mechanism as
described for memory CD4
+ and CD8
+ T cells, not classified
further in these manuscripts according to the distinct stages of T
cell differentiation [15,20,21]. In this context it is of interest for
adoptive T cell therapy that galectin-3 does not co-localize with
and does not block the transgenic CAR in those T cells; CAR
synapse formation occurs in both T cell subsets with same
efficiencies and within the same time frame. Although late-stage T
cells are hypo-responsive to TCR signals, CAR engagement of
antigen mediates effector functions with equal efficiencies as in
Figure 2. TCR synapse formation is impaired in late-stage T cells. CD8
+ CD45RO
+ T lymphocytes were incubated on coverslips coated with
the agonistic anti-CD3 mAb (UCHT-1) plus anti-CD28 mAb (CD28.2) or with the anti-CD2 mAbs (L303.1) and (L304.1) plus the anti-CD28 mAb
(CD28.2). Cells were activated for various time intervals (1 min until 20 min), incubation was stopped by addition of paraformaldehyde, and cells were
stained with TCR-alpha/betamAb (green) plus CD7 mAb (blue) or alternatively with CD2 mAb (blue) plus CD7 mAb (green) together with cholera
toxin B (CtxB) (white) for lipid raft staining. Cells were analyzed on a LSM 510 with 6306microscope magnification. A minimum of 100 cells for each
data point was recorded. Representative images after 0 min, 1 min, 5 min, 10 min and 20 min stimulation out of five independent experiments are
shown. Synapse formation intensity (CTxB intensity) was quantified as described in Materials and Methods. A minimum of 100 cells of each cell
population on each coverslip was recorded. Data represent mean scores from five experiments 6 standard error of the mean and were compared
using a paired t-test. * p,0.05. FU: fluorescence unit.
doi:10.1371/journal.pone.0030713.g002
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30713Figure 3. Galectin-3 prevents TCR synapse formation in late-stage T cells. (A) CD7
2 and CD7
+ T cells were activated by incubation with anti-
CD3 mAb plus anti-human CD28 mAb or as control by an isotype-matched IgG1 (medium). Cells were stained for TCR-alpha/beta (green), CD7 (blue),
CD3 (red) and for galectin-3 (yellow). Immunofluorescence was visualized by a LSM. Alternatively cells were stained with mAbs specific to CD7 and
subsequently recorded for gal-3 expression by staining with the anti-human gal-3mAb or as control by an isotype-matched IgG and analyzed by flow
CAR Overcomes TCR Unresponsiveness
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insufficient TCR synapse formation on the membrane level
through recruitment of the TCR downstream signaling leading to
restoration of a functional T cell response. Experimental data from
other groups help to understand our observations, since it was
published that galectin-3 binds to the TCR-alpha, TCR-beta and
CD3-epsilon chains, but not to the CD3-zeta chain of the TCR
[22,23]. Therefore our data strongly suggest, that a transgenic
CAR, which utilizes a CD3-zeta chain for signal transduction, is
not hampered by galectin-3 interaction with the TCR signal
transduction machinery after antigen recognition. Life imaging
moreover implies that the TCR and the CAR independently form
synapses that is in contrast to the transgenic expression of a
recombinant TCR that can form heterodimers with the physio-
logical TCR [24,25]. Even a modified transgenic TCR that does
not pair with the endogenous TCR localizes in close vicinity to the
endogenous TCR/CD3 in Jurkat T cells [13]. In late-stage T cells
common synapses between physiological and transgenic TCR
likely lead to unresponsiveness of the recombinant TCR making
the redirected T cell response less effective. A single-chain
chimeric antigen receptor, in contrast to the TCR, does not form
common synapses with the physiological TCR although a CAR
makes use of the TCR downstream signaling machinery. This may
not be the case in Jurkat cells as recently reported [14]; those cells,
however, exhibit altered TCR proximal signaling compared to
blood T cells [26].
A significant proportion of T cells from the peripheral blood of
tumor patients and from tumor lesions belong to the terminally
differentiated late-stage T cell subset [16,27]. The number of those
T cells increases with progression of the disease [28]. Current
improvements in adoptive cell therapy therefore aim to prevent
the generation of terminally differentiated T cells by providing a
short-term TCR stimulus to naive CD8
+ T cells sufficient to
induce clonal proliferation, acquisition of effector functions, and
entry into the memory pool in the absence of additional stimuli
[2]. Other approaches make use of pharmacological agents, like
rapamycin, to improve memory formation and to expand the
absolute numbers of both central and effector memory T cells [2].
These strategies may be combined with transgenic expression of a
CAR that circumvents TCR hypo-responsiveness of late-stage T
cells. Late-stage T cells are not only an inevitable result of
repetitive antigen stimulation but also lack CCR7 [7] which has
the advantage that those cells show reduced capability to re-enter
lymph vessels and to re-circulate and are thereby trapped in the
periphery [29] where most tumors are located.
Various physiological T cell subsets are impaired in TCR
synapse formation including orally tolerized T cells [30], T cells
from healthy elderly individuals [31] or T cells under chronic
stimulatory conditions including rheumatoid arthritis or systemic
lupus erythematosus [31]. While hypo-responsiveness in these
lesional T cells is predominantly based on PD-1 - PD-L1/PD-L2
mediated repression [32], it is so far unknown whether the T cell
response in those cells can also be rescued by transgenic CAR
expression.
While late-stage T cells can be rescued for use in the adoptive
immunotherapy, their reduced proliferative capacity and their
accelerated entry into apoptosis need to be addressed. In this
regard CAR-redirected T cell therapy may be combined with
recently developed strategies to sustain telomerase activity, which
leads to improved cytotoxic capacities, cytokine and chemokine
production. Alternatively, TNF-alpha production may be inhib-
ited, which increases the proliferative potential and telomerase
activity in those cells, or transgenic CD28 may be expressed,
which retards replicative senescence [33].
Materials and Methods
Blood samples and cell lines
Buffy coats from healthy young volunteers (n=30) (mean
30610 years) were obtained from the blood bank facilities of the
University Hospital Cologne, Germany. Volunteers who were
taking immunosuppressive drugs or who had a disease potentially
affecting the immune system were excluded. Peripheral blood
from 8 patients (31–74 years) with confirmed diagnosis of active
CMV and lack of HIV infection was analyzed. None of the CMV
patients was on therapy at the time of sampling. All blood samples
were taken after patients gave their written, informed consent.
This study was performed in conformity with the Declaration of
Helsinki of the World Medical Association and approved by the
institutional review committee of the University of Cologne
(reference no 02-041). 293T cells are human embryonic kidney
cells that express the SV40 large T antigen (ATCC CRL 11268).
LS174T (ATCC CCL 188) is a CEA
+ colon carcinoma cell line,
and Colo320 (ATCC CCL 220.1) is a CEA
2 cell line. OKT3
(ATCC CRL 8001) is a hybridoma cell line that produces the anti-
human CD3 monoclonal antibody (mAb) (OKT3); 15E8 hybrid-
oma cells produce the anti-human CD28 mAb (15E8) (obtained
from Dr. Rene van Lier, Red Cross Bloodbank, Amsterdam, The
Netherlands). All cells were cultured in RPMI 1640 medium
(Invitrogen, Karlsruhe, Germany) containing 100 U/ml penicillin,
100 mg/ml streptomycin, 2 mM L-glutamine, and 10% (v/v)
heat-inactivated fetal calf serum (FCS) (Invitrogen).
Antibodies and cytokines
The following antibodies were used: APC-conjugated anti-
TCR-alpha/beta(IP26) (Biolegend, Eching, Germany), PE-Cy7-
conjugated anti-CD8 mAb (RPA-T8) (BD Biosciences, Heidel-
berg, Germany), APC-conjugated anti-CD45RO mAb (UCHL-1)
(BD Biosciences), FITC-conjugated anti-CD7 mAb (4H9) (BD
Biosciences), APC-conjugated anti-CD7 mAb (MEM-186) (Exbio,
Eching, Germany), APC-Cy7-conjugated anti-CD45RO mAb
(UCHL-1) (BD Biosciences), APC-Cy7-conjugated anti-CD3
mAb (UCHT-1) (BD Biosciences), Alexa-488-conjugated anti-
KLRG-1 mAb (13A2) (kindly provided by Dr. H.P. Pircher,
Freiburg, Germany), APC-Cy7-conjugated anti-CD8 mAb (SK1)
cytometry. A representative experiment out of five is shown. Galectin-3 specific signals were quantitatively recorded by a LSM as described in
Materials and Methods. A minimum of 100 cells for each data point was recorded. (B) To monitor location of galectin-3 in lipid raft formation, isolated
CD7
2 and CD7
+ subsets of CD8
+ CD45RO
+ T cells were incubated with or without swainsonine for 24 hrs and then activated for various time intervals
(1 min until 20 min) on coverslips coated with the agonistic anti-CD3 mAb plus anti-CD28 mAb. T cell stimulation was stopped with
paraformaldehyde and cells were stained with anti-TCR-alpha/betamAb (blue), anti-CD7 mAb (red) and anti-galectin-3 mAb (yellow) together with
CtxB (green) for lipid rafts staining. Immunofluorescence was visualized by a LSM and quantified as described in Materials and Methods. T cell staining
after 5 min stimulation of one representative experiment out of five is exemplarily shown. (C) CD7
2 and CD7
+ subsets of CD8
+ CD45RO
+ T cells were
incubated with or without swainsonine and activated as described in (B). Frequencies of cells producing IFN-gamma and showing degranulation
indicated by CD107a was monitored by flow cytometry. Data in Fig. 3 represent the mean 6 SEM of five experiments and were compared using a
paired t-test. * p,0.05. FU: fluorescence unit; MFI: mean fluorescence intensity.
doi:10.1371/journal.pone.0030713.g003
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(Miltenyi Biotec, Bergisch Gladbach, Germany), PE-Alexa-750-
conjugated anti-CD7 mAb (CD7-6B7) (Caltag, Hamburg, Ger-
many), and PE-Cy7-conjugated anti-CD45RO mAb (UCHL-1)
(BD Biosciences). To monitor intracellular galectin-3 expression T
cells were stained with PE-conjugated anti-CD7 mAb (4H9) (BD
Biosciences), fixed and permeabilized, and subsequentially stained
with FITC-conjugated anti-galectin-3 mAb (gal-3) (Mabtech,
Hamburg, Germany). Appropriate isotype antibodies (BD Biosci-
ences) were used as controls. 15E8 and OKT3 mAbs were affinity
purified from hybridoma supernatants utilizing goat anti-mouse
IgG2a antibodies (Southern Biotechnology, Birmingham, Ala-
bama, USA) immobilized on N-hydroxy-succinimid-ester-(NHS)-
activated sepharose (Amersham Biosciences, Freiburg, Germany).
Cells were analyzed by flow cytometry using a FACS Calibur or
FACSCanto cytometer (BD Biosciences), equipped with Cell
Quest or FACS DIVA software (BD Biosciences). Viable
lymphocytes were gated according to forward/side scatter and
lack of 7-AAD (BD Biosciences) staining. Human recombinant
interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) were
purchased from R&D Systems (Wiesbaden, Germany). IFN-
gamma in the culture medium was recorded by ELISA utilizing
matched pairs of specific antibodies (clones NIB 42 and B133.5,
BD Biosciences). The detection limit of the assay is 15 pg/ml IFN-
gamma.
Cell sorting
CD8
+ CD45RO
+ T cells were obtained from peripheral blood
mononuclear cells by negative depletion magnetic cell sorting
(MACS) (Miltenyi Biotec) using the ‘‘CD8
+ T cell isolation kit’’
and anti-human CD45RA microbeads. CD8
+ CD45RO
+ T cells
were separated into CD7
+ and CD7
2 subpopulations by using the
FITC-conjugated anti-human CD7 antibody (4H9) (BD Biosci-
ences) and anti-FITC microbeads (Miltenyi Biotec). CD8
+ T cells
were obtained from peripheral blood mononuclear cells by
positive selection using anti-human CD8
+ microbeads (Miltenyi
Biotec). The purity of the isolated T cell subpopulations was
routinely .95%.
CAR mediated T cell activation
The generation of the retroviral expression cassettes for the
CEA-specific CAR BW431/26scFv-Fc-CD3-zeta(#439) and ret-
roviral transduction of T cells was described in detail [34]. Briefly,
retroviral vector DNA was cotransfected with the helper plasmid
DNAs pHIT60 and pCOLT (each at 1 mg DNA/10
5 cells) into
293T cells for virus production. T cells were activated by addition
of IL-2 (1,000 units/ml) and OKT3 mAb (100 ng/ml) for 48 hrs
and incubated with retroviruses for additional 48 hrs. CAR
expression was monitored by flow cytometry using a PE-
conjugated F(ab9)2 anti-human IgG1 antibody (1 mg/ml) (South-
ern Biotechnology), which recognizes the extracellular IgG1
CH2CH3 domain of the CAR, and a FITC-conjugated anti-
human CD3 mAb (UCHT-1) (BD Biosciences). After 24 hrs
without stimuli redirected cytolysis was recorded by incubating T
cells in increasing numbers with tumor cells (2.5610
4 per well) for
48 hrs in round-bottom 96-well plates, specific cytotoxicity
monitored by a XTT-based colorimetric assay (Roche Applied
Science, Mannheim, Germany) and the viability of tumor cells was
calculated as follows:
viability % ½  :
OD experimental wells{corresponding number of effector cells ðÞ ½ =
OD tumor cells without effector cells{medium ðÞ   |100:
CMV specific T cells
CD8
+ T cells from CMV infected, HIV
2 donors were stained
for HLA-A2 with mAb (BB7.2) (BD Biosciences). Tetramer-
binding T cells were detected by incubation with the PE-
conjugated MHC tetrameric complexes HLA-A*0201/pp65
495–
503 (Sanquin, Amsterdam, The Netherlands). Intracellular IFN-
gamma was detected in PBMC’s from CMV patients stimulated
for 6 hrs in presence with PE-conjugated MHC tetrameric
complexes HLA-A*0201/pp65
495–503 (Sanquin) together with
CMV peptide NLVPMVATV (‘‘CMV pp65 Peptide Mix’’) or
the TCR cross-linking reagent ‘‘Cytostim’’ (both from Miltenyi
Biotec) or HIV peptide SLYNTVATL (JPT, Berlin, Germany),
respectively, and stained for CD8, CD7 and CD45RO. During the
final 5 hrs, brefeldin A (5 mg/ml) (BD Biosciences) was added to
avoid release of cytokines from the Golgi apparatus, respectively,
and cells were subsequently stained for IFN-gamma using the
clone 25723.11 mAb (BD Biosciences). Alternatively, lymphocytes
were activated for 6 hrs in presence of FITC-conjugated anti-
CD107a mAb (H4A3) (BD Biosciences), the CMV peptide, and
the agonistic anti-CD49d mAb (L25) (1 mg/ml) plus the anti-CD28
mAb (L293) (1 mg/ml) (both from BD Biosciences).
Synapse formation
T cells (10
5 cells) were placed on cover slips coated with poly-L-
lysine (0.1 mg/ml) (Sigma Aldrich, Deisenhofen, Germany), the
anti-CD3 mAb (UCHT-1) and the anti-CD28 mAb (CD28.2) or
with the anti-CD2 mAbs (L303.1) and (L304.1) and the anti-CD28
mAb (CD28.2), or as control by an isotype-matched IgG1 (all from
BD Biosciences; 10 mg/ml each). Alternatively, cover slips were
coated with the BW2064/36 mAb (10 mg/ml), which is an internal
image anti-idiotypic antibody, directed against the anti-CEA scFv
BW431/26 [35]. Cells were activated for various time intervals
(1 min until 20 min) and incubation was stopped by addition of
Figure 4. CAR triggered activation is as efficient in late-stage as in intermediate-stage T cells. (A) Isolated CD7
2 and CD7
+ subset cells of
CD8
+ CD45RO
+ T cells were engineered with the CEA-specific CAR BW431/26scFv-Fc-CD3-zeta by retroviral gene transfer. CAR expression was
monitored by flow cytometry with a PE-conjugated anti-IgG1 mAb and a FITC-conjugated anti-CD3 mAb. Dot plots of one representative
transduction of CD7
2 and CD7
+ T cells from five independent experiments is shown (B) CAR modified T cells were activated for various time intervals
(1 min until 20 min) on coverslips coated with the BW2064/36 mAb. The incubation was stopped with paraformaldehyde and cells were stained for
TCR (green), CD7 (blue), CAR (red) and CtxB (yellow). Imaging after 5 min of activation is exemplarily shown. Synapse formation intensity (CTxB
intensity) was quantified as described in Materials and Methods. (C) To monitor location of galectin-3 upon CAR-mediated activation, engineered
CD7
2 and CD7
+ T cells were activated by the BW2064/36 mAb or an isotype-matched control antibody of irrelevant specificity as described in (B).
Cells were stained for TCR-alpha/beta(green), CD7 (blue), CAR (red) and for galectin-3 (yellow). Imaging after 5 min of T cell activation of one
representative experiment out of five is exemplarily shown. (D) To monitor CAR-mediated effector functions, CAR engineered CD7
2 and CD7
+ T cells
in increasing numbers were co-incubated with CEA
+ LS174T and CEA
2 Colo320 tumor cells, respectively. IFN-gamma in the culture supernatants after
48 hrs was monitored by ELISA. Viability of tumor cells was colorimetrically determined by XTT assay. Data in Fig. 4 represent the mean of five
experiments 6 SEM and were compared using a paired t-test. * p,0.05. FU: fluorescence unit.
doi:10.1371/journal.pone.0030713.g004
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with 2% (v/v) human AB serum (PAA Laboratories, Coelbe,
Germany) for 20 min. Synpase formation was recorded as
described [36]. Briefly, cells were stained with Alexa 647- or
Alexa-488-labeled cholera toxin B subunit (CTxB) (Invitrogen) for
staining lipid rafts (GM1) and stained for TCR-alpha/beta(IP26)
(Biolegend), CD7 (MEM-186) (Exbio), CD2 (TS1/8) (Biolegend),
IgG to indicate the CAR (Medac, Hamburg, Germany), CD3
(UCHT-1) (Biolegend) and galectin-3 (M3/38) (Biolegend).
Formation of synapses was indicated by accumulation of CTxB
at the cell-cover slip interface as assessed by confocal laser
scanning microscopy using the LSM 510 (Karl Zeiss, Oberkochen,
Germany) equipped with Zen 2009 software with 6306 micro-
scope magnification. A region with accumulated TCR or CAR
molecules together with an accumulation of CTxB was considered
a synapse. To quantitate the recruitment of TCR and CAR to the
immunological synapse, gates were automatically drawn around (i)
the immunological synapse, (ii) the regions of the T cell not in
contact with agonistic antibodies, and (iii) a background area. The
relative recruitment index (RRI) shown in figures as CTxB
intensity (relative mean fluorescence of synapse formation) was
calculated as indicated: (mean fluorescence intensity (MFI) at
synapse – background)/(MFI at all the cell membrane not in
contact with agonistic antibodies – background). Quantitative
analysis of MFI was performed automatically with the Image J
programme (NIH, Maryland, USA). A minimum of 100 cells for
each data point was examined quantitatively for each experiment.
To block alpha-mannosidase II, T cells were incubated with
swainsonine (0.5 mM) (Calbiochem, Darmstadt, Germany) for
24 hrs. Specificity of staining was assayed by incubation with the
respective isotype-matched control antibody (BD Biosciences).
Finally, all slides were coverslipped with Entellan (ProSciTec,
Thuringowa, Australia) and analyzed by laser scan microscopy
(LSM).
Statistical analyses
Results are presented as means 6 standard error of the mean
(SEM). A paired and unpaired two-tailed t-test was used; p,.05
was considered significant.
Supporting Information
Figure S1 CMV-specific T cells in late-stage and
intermediate-stage of terminal differentiation equally
bind pp65 CMV tetramers. CMV-specific CD8
+ T cells in
late or intermediate stage of terminal differentiation were
identified in the peripheral blood from CMV patients with acute
virus reactivation by incubation with PE-conjugated CMV peptide
loaded tetramers HLA-A*0201/pp65
495–503 and staining for CD8,
CD7, CD45RO, CD57, KLRG-1, CD3 and TCR-alpha/beta as
described in Materials and Methods. Cells were analyzed by flow
cytometry. One representative donor out of five CMV patients is
shown.
(PDF)
Figure S2 CD7
2 late-stage T cells are hypo-responsive
to TCR/CD3 stimulation. The CD7
2 and CD7
+ subsets of
CD8
+ CD45RO
+ T cells were isolated from the peripheral blood
and cultured (10
5 cells/100 ml) with or without the agonistic anti-
CD3 mAb (OKT3) (5 mg/ml), the anti-CD28 mAb (15E8) (5 mg/
ml), or with IL-2 (50 U/ml). (A) IFN-gamma in the culture
supernatant at day 6 was detected by ELISA. (B) To monitor
CD107a
+ IFN-gamma producing cells, cells were monitored by
flow cytometry by staining with the PE-conjugated anti-IFN-
gamma mAb (25723.11) and the FITC-conjugated anti-CD107a
mAb (H4A3). Assays (Figs. S2A & B) were performed five times
and the mean values 6 SEM are shown. Statistical analyses were
made using a paired t-test. * p,0.05, CD7
2 cells compared with
the corresponding CD7
+ T cells.
(PDF)
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